rabeprazole has been researched along with Stomach Neoplasms in 18 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 9.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 9.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 5.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)." | 5.22 | Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 5.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "Patients with early gastric cancers that are limited to gastric mucosa or submucosa usually have an advanced loss of mucosal glandular tissue (glandular atrophy) and are at high risk for subsequent (metachronous) development of new gastric cancer." | 2.87 | Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Nam, BH; Park, B, 2018) |
| "Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear." | 2.78 | Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer. ( Hong, JH; Jo, KW; Kim, BR; Kim, HS; Kim, JW; Park, HJ; Park, SY, 2013) |
| "A total of 138 distal gastric cancer patients with H." | 2.73 | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. ( Bae, JM; Choi, IJ; Hong, EK; Kim, CG; Kim, YW; Kook, MC; Lee, JH; Lee, JY; Park, S; Ryu, KW; Song, HJ, 2008) |
| " Several studies have linked the long-term use of PPIs to a potentially increased risk of gastric cancer." | 1.72 | Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors. ( Lee, WP, 2022) |
| "Rabeprazole has also been shown to have a more consistent suppression of acid, including at night." | 1.31 | Optimizing acid-suppression therapy. ( Barnett, JL; Robinson, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, WP | 1 |
| Kono, Y | 1 |
| Kusumoto, C | 1 |
| Kiguchi, T | 1 |
| Okada, H | 1 |
| Yamasaki, A | 1 |
| Yoshio, T | 1 |
| Muramatsu, Y | 1 |
| Horiuchi, Y | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Sasaki, Y | 1 |
| Fujisaki, J | 1 |
| Choi, IJ | 2 |
| Kook, MC | 2 |
| Kim, YI | 1 |
| Cho, SJ | 1 |
| Lee, JY | 2 |
| Kim, CG | 2 |
| Park, B | 1 |
| Nam, BH | 1 |
| Bang, CS | 1 |
| Shin, WG | 1 |
| Seo, SI | 1 |
| Choi, MH | 1 |
| Jang, HJ | 1 |
| Park, SW | 1 |
| Kae, SH | 1 |
| Yang, YJ | 1 |
| Shin, SP | 1 |
| Baik, GH | 1 |
| Kim, HY | 1 |
| Baeg, MK | 1 |
| Choi, MG | 1 |
| Moon, SJ | 1 |
| Lim, CH | 1 |
| Kim, JS | 1 |
| Cho, YK | 1 |
| Park, JM | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Choi, KY | 1 |
| Hikichi, T | 1 |
| Sato, M | 1 |
| Watanabe, K | 1 |
| Nakamura, J | 1 |
| Takagi, T | 1 |
| Suzuki, R | 1 |
| Sugimoto, M | 1 |
| Waragai, Y | 1 |
| Kikuchi, H | 1 |
| Konno, N | 1 |
| Ohira, H | 1 |
| Obara, K | 1 |
| Mitsui, Y | 1 |
| Kagemoto, K | 1 |
| Itagaki, T | 1 |
| Inoue, S | 1 |
| Naruse, K | 1 |
| Muguruma, N | 1 |
| Takayama, T | 1 |
| Nakamura, K | 1 |
| Ihara, E | 1 |
| Akiho, H | 1 |
| Akahoshi, K | 1 |
| Harada, N | 1 |
| Ochiai, T | 1 |
| Nakamura, N | 1 |
| Ogino, H | 1 |
| Iwasa, T | 1 |
| Aso, A | 1 |
| Iboshi, Y | 1 |
| Takayanagi, R | 1 |
| Kagawa, T | 1 |
| Iwamuro, M | 1 |
| Ishikawa, S | 1 |
| Ishida, M | 1 |
| Kuraoka, S | 1 |
| Sasaki, K | 1 |
| Sakakihara, I | 1 |
| Izumikawa, K | 1 |
| Yamamoto, K | 1 |
| Takahashi, S | 1 |
| Tanaka, S | 1 |
| Matsuura, M | 1 |
| Hasui, T | 1 |
| Wato, M | 1 |
| Inaba, T | 1 |
| Fujiwara, S | 1 |
| Morita, Y | 1 |
| Toyonaga, T | 1 |
| Kawakami, F | 1 |
| Itoh, T | 1 |
| Yoshida, M | 1 |
| Kutsumi, H | 1 |
| Azuma, T | 1 |
| Niimi, K | 1 |
| Fujishiro, M | 1 |
| Goto, O | 1 |
| Kodashima, S | 1 |
| Minatsuki, C | 1 |
| Hirayama, I | 1 |
| Mochizuki, S | 1 |
| Ono, S | 1 |
| Yamamichi, N | 1 |
| Kakushima, N | 1 |
| Ichinose, M | 1 |
| Koike, K | 1 |
| Park, HJ | 1 |
| Kim, HS | 1 |
| Kim, BR | 1 |
| Park, SY | 1 |
| Hong, JH | 1 |
| Jo, KW | 1 |
| Kim, JW | 1 |
| Go, MF | 1 |
| Onoda, N | 1 |
| Katsuragi, K | 1 |
| Sawada, T | 1 |
| Maeda, K | 1 |
| Mino, A | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Wakasa, K | 1 |
| Hirakawa, K | 1 |
| Uedo, N | 1 |
| Takeuchi, Y | 1 |
| Yamada, T | 1 |
| Ishihara, R | 1 |
| Ogiyama, H | 1 |
| Yamamoto, S | 2 |
| Kato, M | 1 |
| Tatsumi, K | 1 |
| Masuda, E | 1 |
| Tamai, C | 1 |
| Higashino, K | 1 |
| Iishi, H | 1 |
| Tatsuta, M | 1 |
| Song, HJ | 1 |
| Hong, EK | 1 |
| Park, S | 1 |
| Lee, JH | 1 |
| Ryu, KW | 1 |
| Kim, YW | 1 |
| Bae, JM | 1 |
| Barnett, JL | 1 |
| Robinson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer[NCT02407119] | Phase 3 | 470 participants (Actual) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer.[NCT02638584] | Phase 4 | 176 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm[NCT02005809] | Phase 3 | 268 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for rabeprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mu | 2021 |
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2002 |
10 trials available for rabeprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug | 2018 |
Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Fema | 2019 |
Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Female; Gastric Mucosa; Gastrointestinal | 2014 |
Oral rabeprazole administration on a procedure day suppresses bleeding after endoscopic submucosal dissection for gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Administration, Oral; Aged; Aged, 80 and over; Female; Gastrointestinal Hem | 2014 |
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; | 2016 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; | 2016 |
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug | 2011 |
Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Double-Blind Method; Female; Gastroscopy; Humans; Mal | 2013 |
Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cimetidi | 2007 |
Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
6 other studies available for rabeprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.
Topics: Activating Transcription Factor 6; Dexlansoprazole; Endoplasmic Reticulum Stress; Esomeprazole; Huma | 2022 |
Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Drug Substitution; Endoscopic Mucosal R | 2018 |
Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Endoscopy, Digestive System; Gastritis, Atrophic | 2015 |
Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Carcinom | 2012 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2005 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2001 |